Affymetrix (Nasdaq: AFFX) announced the launch of Concurrent Molecular Analysis Profiling (CoMAP™) capability, which enables cancer researchers to gain rapid ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE